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1. INTRODUCTION {#cam41973-sec-0001}
===============

Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma, accounting for 30%‐40% of non‐Hodgkin lymphoma.[1](#cam41973-bib-0001){ref-type="ref"} Although rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) has led to a remarkable improvement in the treatment of DLBCL patients,[2](#cam41973-bib-0002){ref-type="ref"} considerable proportion of the patients fail to cure.[3](#cam41973-bib-0003){ref-type="ref"} To date, many prognostic factors are advocated, including patient factors: age, performance status (PS),[3](#cam41973-bib-0003){ref-type="ref"} Charlson Comorbidity Index,[4](#cam41973-bib-0004){ref-type="ref"} tumor burden; LDH,[5](#cam41973-bib-0005){ref-type="ref"} clinical stage,[5](#cam41973-bib-0005){ref-type="ref"} and biological features of tumor cells; and germinal center B‐cell (GCB) type or non‐GCB type,[6](#cam41973-bib-0006){ref-type="ref"}, [7](#cam41973-bib-0007){ref-type="ref"} CD5‐positivity,[8](#cam41973-bib-0008){ref-type="ref"} status of Epstein‐Barr virus,[9](#cam41973-bib-0009){ref-type="ref"} and double‐hit lymphoma.[10](#cam41973-bib-0010){ref-type="ref"} These factors should be considered comprehensively at diagnosis to estimate the prognosis of the patients with DLBCL.

^18^F‐FDG PET/CT is widely performed at initial staging in DLBCL patients. High total metabolic tumor volume (TMTV) calculated using ^18^F‐FDG PET/CT images at diagnosis is predictive of poor prognosis of DLBCL, follicular lymphoma (FL), and peripheral T‐cell lymphoma.[11](#cam41973-bib-0011){ref-type="ref"}, [12](#cam41973-bib-0012){ref-type="ref"}, [13](#cam41973-bib-0013){ref-type="ref"}, [14](#cam41973-bib-0014){ref-type="ref"} However, not all patients can undergo ^18^F‐FDG PET/CT due to various reasons, including high cost, poor access to the imaging facilities, and urgent requirement for treatment initiation, encouraging us to explore a surrogate marker for metabolic tumor volumes. Several previous studies have shown that serum level of sIL‐2R is a prognostic biomarker of DLBCL.[15](#cam41973-bib-0015){ref-type="ref"}, [16](#cam41973-bib-0016){ref-type="ref"} In the current study, we retrospectively evaluated the correlation between the serum levels of sIL‐2R and TMTV based on ^18^F‐FDG PET/CT images at diagnosis and compared the role of these parameters as prognostic biomarker in newly diagnosed DLBCL.

2. PATIENTS AND METHODS {#cam41973-sec-0002}
=======================

2.1. Patients {#cam41973-sec-0003}
-------------

In the training cohort, we reviewed the medical records of 64 consecutive adult patients with DLBCL newly diagnosed according to the 4th Edition of World Health Organization (WHO) classification at Aiiku Hospital from 2008 to 2014. In the validation cohort, we reviewed the medical records of 86 patients with DLBCL newly diagnosed at Sapporo Hokuyu Hospital from 2008 to 2013. All patients in the training cohort underwent ^18^F‐FDG PET/CT at Central CI clinic (Sapporo, Japan) with PET/CT device (Discovery ST Elite^®^; GE Healthcare, Tokyo, Japan, or GEMINI^®^; Philips, Tokyo, Japan), and those in the validation cohort underwent ^18^F‐FDG PET/CT at Keiyukai Sapporo Hospital (Sapporo, Japan), with PET/CT device (GEMINI^®^ GXL; Philips, Tokyo, Japan) before initiation of chemotherapy. We did not cross calibrate cameras for PET/CT at these two facilities. Serum levels of sIL‐2R were measured using chemiluminescent enzyme immunoassay (CLIA; STACIA^®^; LSI Medience, Tokyo, Japan) in the training cohort, while those were measured using enzyme‐linked immunosorbent assay (ELISA; IL‐2Rtest^®^; BML, Tokyo, Japan) in the validation cohort. The study procedures were in accordance with the Helsinki Declaration and institutional ethical guidelines, conducted under the auspices of the institutional ethics committee, and approved by the institutional review boards of each institute. Clinical stage was determined according to the Ann Arbor staging system, and treatment response was evaluated according to the International Workshop criteria.[17](#cam41973-bib-0017){ref-type="ref"} NCCN‐IPI scores were calculated as previously described.[5](#cam41973-bib-0005){ref-type="ref"}

2.2. PET/CT parameters {#cam41973-sec-0004}
----------------------

Standardized uptake value (SUV) was calculated as \[tissue radioactivity concentration (Bq/mL)\] × \[body weight (g)\]/\[injected radioactivity (Bq)\]. TMTV was defined as the volume of lymphoma visualized on PET/CT scans with SUV greater than or equal to an absolute threshold of 4.0, as previously described.[18](#cam41973-bib-0018){ref-type="ref"} SUV computer‐aided analysis of PET/CT images for TMTV calculations was performed using Metavol (Hokkaido University, Sapporo, Japan, <http://www.metavol.org/home>),[19](#cam41973-bib-0019){ref-type="ref"} with exclusion of physiological accumulation including urinary, myocardial, and brain FDG uptake. Nodular or heterogeneous uptake in the bone marrow was included as tumor involvement based on radiologist\'s interpretation, while diffuse uptake was considered as physiological uptake. All quantitative parameters were retrospectively measured by a nuclear medicine physician (ET) in a blinded fashion.

2.3. Statistical analysis {#cam41973-sec-0005}
-------------------------

Overall survival (OS) was calculated from the day of diagnosis until death or last follow‐up. Event‐free survival (EFS) was defined as time from diagnosis to disease progression, relapse after response, death, or last follow‐up. The probabilities of OS and EFS were estimated using a Kaplan--Meier method, and differences between patient groups were analyzed using the log‐rank test. The baseline patient characteristics were tabulated to check imbalance in the demographic information. The risk factors at diagnosis for OS or EFS were evaluated by multivariate Cox regression using stepwise variable selection. Analysis of contingency data of sIL‐2R and TMTV was carried out using Fisher\'s exact test (categorical variables) and Mann‐Whitney *U* test (continuous variables). Youden Index was calculated to determine optimal cutoff value of these parameters in receiver operating curve (ROC) analysis with regarding failure in achievement of 2‐year EFS (EFS24) [20](#cam41973-bib-0020){ref-type="ref"}, [21](#cam41973-bib-0021){ref-type="ref"} as positive finding. The correlation between sIL‐2R and TMTV was assessed by using Pearson\'s product‐moment correlation coefficient, respectively. All *P*‐values were 2‐sided, and a *P*‐value of 0.05 was used as the cutoff for statistical significance. All the statistical analyses were performed with the EZR (<http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html>).[22](#cam41973-bib-0022){ref-type="ref"}

3. RESULTS {#cam41973-sec-0006}
==========

3.1. Patient characteristics {#cam41973-sec-0007}
----------------------------

Baseline patient characteristics were listed in Table [1](#cam41973-tbl-0001){ref-type="table"}. In the training cohort, the median patient age at diagnosis was 74 years, ranging from 33 to 86 years. PS was 2 or greater in 30% of the patients, and 81% of the patients had stage III or IV. Sixty‐six percent of the patients had extranodal involvement, including bone marrow (17%), and 58% presented with B‐symptoms. Sixty‐seven percent of the patients had elevated serum LDH value than normal level. For NCCN‐IPI scores, 24%, 31%, and 45% of the patients were classified as Low or Low‐intermediate (Low‐int) risk group, High‐intermediate (High‐int) risk group, and High‐risk group, respectively.

###### 

Patient characteristics

  ----------------------------------------------------------------------------------------------------
  Characteristics            Training cohort\              Validation cohort\              *P* value
                             No. (%)                       No. (%)                         
  -------------------------- ----------------------------- ------------------------------- -----------
  Sex (male/female)          31/33                         44/42                           0.512

  Age (median y, range)      74 (33‐86)                    71 (24‐90)                      0.019

  ECOG Performance status                                                                  \<0.01

  0, 1                       45 (70)                       81 (94)                         

  ≥2                         19 (30)                       5 (6)                           

  Stage                                                                                    \<0.01

  I, II                      12 (19)                       54 (63)                         

  III                        13 (20)                       11 (13)                         

  IV                         39 (61)                       21 (24)                         

  Extranodal sites                                                                         0.281

  0                          33 (34)                       60 (70)                         

  ≥1                         42 (66)                       26 (30)                         

  Bone marrow involvement                                                                  0.541

  Yes                        11 (17)                       10 (12)                         

  No                         53 (83)                       76 (88)                         

  B symptoms                                                                               0.330

  Yes                        29 (58)                       12 (14)                         

  No                         35 (42)                       74 (86)                         

  LDH                                                                                      0.285

  ≤Normal                    21 (33)                       45 (52)                         

  ≥Normal                    43 (67)                       41 (48)                         

  sIL‐2R                                                                                   0.409

  Median (range)             1735 (243‐43 700) U/mL        1274 (200‐39 798) U/mL          

  \<1300                     27 (42)                       40 (47)                         

  ≥1300                      37 (58)                       46 (53)                         

  TMTV                                                                                     0.411

  Median (range)             236.32 (76.62‐677.09) cm^3^   167.2305 (4.61‐5445.50) cm^3^   

  \<150                      26 (41)                       44 (51)                         

  ≥150                       38 (59)                       42 (49)                         

  NCCN‐IPI                                                                                 0.014

  Low, Low‐int               15 (24)                       47 (55)                         

  High‐int                   20 (31)                       33 (38)                         

  High                       29 (45)                       6 (7)                           

  Treatment                                                                                \<0.01

  R‐CHOP                     27(42)                        81(94)                          

  R‐THP‐COP                  36(56)                        5(6)                            

  R‐CVP                      1(2)                          0(0)                            

  Outcome                                                                                  

  CR                         42 (66)                       69 (80)                         0.0594

  PR                         7(11)                         2(2)                            0.0378

  Residual disease           18 (28)                       18 (21)                         0.338

  Relapse                    16 (25)                       14 (16)                         0.218

  Death from disease         12 (19)                       5 (6)                           0.0184

  Treatment‐related death    11 (17)                       8 (9)                           0.214

  Death from other reasons   5 (8)                         2 (2)                           0.134
  ----------------------------------------------------------------------------------------------------

CR, complete remission; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NCCN‐IPI, National Comprehensive Cancer Network‐International Prognostic Index; PR, partial remission; residual disease includes the patient with PR, stable disease, and progressive disease.; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R‐CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; R‐THP‐COP, rituximab, therarubicin, cyclophosphamide, vincristine, and prednisone; sIL‐2R, soluble interleukin‐2 receptor; TMTV, total metabolic tumor volume.

John Wiley & Sons, Ltd

3.2. Treatment and outcome {#cam41973-sec-0008}
--------------------------

Patients in the training cohort were initially treated with R‐CHOP or R‐CHOP‐like chemotherapies (R‐THP‐COP: rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisone; R‐CVP: cyclophosphamide, vincristine, and prednisolone).[23](#cam41973-bib-0023){ref-type="ref"}, [24](#cam41973-bib-0024){ref-type="ref"} Nineteen percent of the patients received additional involved field radiation therapy following completion of chemotherapy. Overall response was 77% (CR + CRu: 66%, PR: 11%). With a median follow‐up period of 32.8 months, ranging from 1.4 to 111.5 months, an estimated OS rate was 53.1% (95% CI: 39.5%‐64.9%) and EFS rate was 45.4% (95% CI: 32.5%‐57.4%) at 5 years (Figure [1](#cam41973-fig-0001){ref-type="fig"}).

![Kaplan‐Meier plots of OS (A) and EFS (B) of patients in the training cohort (n = 64)](CAM4-8-953-g001){#cam41973-fig-0001}

3.3. sIL‐2R levels correlated with TMTV {#cam41973-sec-0009}
---------------------------------------

Pearson\'s correlation tests demonstrated highly significant positive correlation between sIL‐2R and TMTV (*R* ^2^ = 0.490; *P* = 0.00004, Figure [2](#cam41973-fig-0002){ref-type="fig"}A).

![Correlation of sIL‐2R level with TMTV. In the training population (n = 64), positive correlation between sIL‐2R and TMTV (Pearson *R* ^2^ = 0.490; *P* = 0.00004) (A) is shown. Positive correlation between sIL‐2R and TMTV (Pearson *R* ^2^ = 0.461; *P* = 0.00000631) (B) in the validation cohort (n = 86) is shown](CAM4-8-953-g002){#cam41973-fig-0002}

3.4. Quantitative PET parameters as prognostic biomarkers {#cam41973-sec-0010}
---------------------------------------------------------

In the training population, the mean TMTV was 460.45 cm^3^ (median 236.32 cm^3^, 25th‐75th percentiles 76.62‐677.09 cm^3^). ROC analysis revealed that the cutoff value of TMTV \<150 cm^3^ could predict achievement of EFS24 (Figure [3](#cam41973-fig-0003){ref-type="fig"}A). AUC was 0.706 (95% CI: 0.570‐0.841; *P* = 0.00288). The 150 cm^3^ cutoff value for TMTV had a sensitivity and a specificity of 60.6% and 90.3%, respectively, for achievement of EFS24. OS and EFS were significantly lower in patients with TMTV ≥150 cm^3^ than in those with less than 150cm^3^ (5‐year OS; 84.0% vs 29.1%, *P = *0.000194, 5‐year EFS; 71.4% vs 28.7%, *P = *0.000384 (Figure [3](#cam41973-fig-0003){ref-type="fig"}B, C).

![ROC according to TMTV. In the training cohort, with regarding failure in achievement of 2‐year EFS as positive finding, ROC according to TMTV (A) is shown. Kaplan‐Meier plots of OS (B) and EFS (C) according to TMTV is shown (n = 64)](CAM4-8-953-g003){#cam41973-fig-0003}

3.5. sIL‐2R level at diagnosis as a prognostic biomarker {#cam41973-sec-0011}
--------------------------------------------------------

In the training cohort, the median serum sIL‐2R level at diagnosis was 1735 U/mL, ranging from 243 to 43 700 U/mL. ROC analysis revealed that the cutoff value of sIL‐2R \<1300 U/mL could predict achievement of EFS24 (Figure [4](#cam41973-fig-0004){ref-type="fig"}A). AUC was 0.758 (95% CI: 0.638‐0.877; *P* = 0.0000233). The 1300 U/mL cutoff value for sIL‐2R had a sensitivity and a specificity of 66.7% and 83.9%, respectively, for achievement of EFS24. Kaplan--Meier curves showed that sIL‐2R ≥1300 U/mL was a strong prognostic factor both for worse OS and EFS (5‐year OS; 85.2% vs 25.9%, *P = *0.000035, 5‐year EFS; 72.0% vs 26.8%, *P = *0.000076; Figure [4](#cam41973-fig-0004){ref-type="fig"}B, C).

![ROC according to sIL‐2R With regarding failure in achievement of 2‐y EFS as positive finding, a ROC according to sIL‐2R (A) is shown. Kaplan‐Meier plots of OS (B) and EFS (C) according to sIL‐2R were shown](CAM4-8-953-g004){#cam41973-fig-0004}

3.6. Univariate and multivariate analyses of clinical prognostic factors {#cam41973-sec-0012}
------------------------------------------------------------------------

NCCN‐IPI was predictive for 5‐year OS (NCCN‐IPI: Low/Low‐Int, 93.3%; High‐Int, 59.2%; High, 23.0%, *P* = 0.000147) and 5‐year EFS (NCCN‐IPI: Low/Low‐Int, 83.0%; High‐Int, 54.0%; High, 23.0%, *P* = 0.000307; Figure [S1](#cam41973-sup-0001){ref-type="supplementary-material"}). We analyzed various prognostic factors for OS and EFS (Table [2](#cam41973-tbl-0002){ref-type="table"}). In a univariate analysis, B symptom, LDH, sIL‐2R, and TMTV were associated with poor 5‐year OS; B symptom, LDH, PS, sIL‐2R, and TMTV were identified as poor prognostic factors for 5‐year EFS. We therefore performed multivariate analysis that included sIL‐2R and all factors in NCCN‐IPI; age, LDH, clinical stage, ECOG PS, and major organ involvement.[5](#cam41973-bib-0005){ref-type="ref"} Although serum levels of sIL‐2R were significantly higher in patients with PS ≥ 2, elevated LDH, or CS ≥ III, age and sIL‐2R were independently associated with poor 5‐year OS (age; HR, 4.44; 95% CI: 1.05‐18.7, *P* = 0.0424, sIL‐2R; HR, 4.45; 95% CI: 1.04‐19.1, *P* = 0.0444; Table [3](#cam41973-tbl-0003){ref-type="table"} and Table [S1](#cam41973-sup-0005){ref-type="supplementary-material"}). Another multivariate analysis that included TMTV and all factors for NCCN‐IPI demonstrated that TMTV was an only independent prognostic factor for 5‐year OS (HR: 3.87; 95% CI: 1.08‐13.8; log‐rank, *P* = 0.0373; Table [3](#cam41973-tbl-0003){ref-type="table"}). We performed an additional multivariate analysis including both TMTV and sIL‐2R We found that neither TMTV nor sIL‐2R persisted as an independent prognostic factor after this multivariate analysis, further confirming the strong correlations between TMTV and sIL‐2R (Table [3](#cam41973-tbl-0003){ref-type="table"}).

###### 

Univariate analysis of the risk factors associated with 5‐y OS and EFS

  Characteristics           Training cohort   Validation cohort                                        
  ------------------------- ----------------- ------------------- ------ -------- ------ ------ ------ --------
  Sex                                         0.8                        0.81            0.55          0.08
  Male                      51.7                                  44.8            11.4          52.3   
  Female                    57.1                                  48.6            16.7          71.4   
  Age                                         0.53                       0.10            0.07          0.64
  \<70                      31.6                                  68.4            23.8          73.8   
  ≥70                       22.2                                  44.4            22.0          68.2   
  ECOG Performance Status                     0.12                       \<0.01          1.00          0.32
  \<2                       31.1                                  64.4            14.7          64.0   
  ≥2                        10.5                                  21.1            9.1           45.5   
  Stage                                       0.48                       0.11            0.76          0.11
  \<Stage III               50.0                                  75.0            13.0          68.5   
  ≥Stage III                42.3                                  46.2            15.6          50.0   
  Extranodal sites                            0.07                       0.07            0.50          0.81
  0                         40.9                                  68.0            11.7          60.0   
  ≥1                        16.7                                  42.9            19.2          65.4   
  Bone marrow involvement                     0.52                       0.21            0.63          0.50
  Yes                       50.0                                  38.2            20.0          50.0   
  No                        60.0                                  56.7            13.2          63.2   
  B symptoms                                  \<0.01                     \<0.01          0.67          1.00
  Yes                       31.0                                  27.6            16.7          58.3   
  No                        74.3                                  62.9            13.5          62.2   
  LDH                                         0.03                       \<0.01          0.76          0.08
  ≤Normal                   42.7                                  80.9            15.6          71.1   
  \>Normal                  16.3                                  37.2            12.2          65.4   
  sIL‐2R                                      \<0.01                     \<0.01          0.21          \<0.01
  ≤1300 U/mL                51.8                                  74.0            20.0          80.0   
  \>1300 U/mL               8.1                                   27.0            8.7           45.7   
  TMTV                                        \<0.01                     \<0.01          0.03          \<0.01
  ≤150 cm^3^                24.0                                  80.8            22.7          77.3   
  \>150 cm^3^               7.9                                   31.6            4.8           59.4   

ECOG, Eastern Cooperative Oncology Group; EFS, event‐free survival; LDH, lactate dehydrogenase; OS, overall survival; sIL‐2R, soluble interleukin‐2 receptor; TMTV, total metabolic tumor volume.

Major organ involvement is defined as lymphomatous involvement in bone marrow, central nerve system, liver, gastrointestinal tract, or lung.

John Wiley & Sons, Ltd

###### 

Multivariate analysis of the risk factors associated with 5‐y OS

  Characteristics                      Training cohort   Validation cohort                             
  ------------------------------------ ----------------- ------------------- ------ ------ ----------- --------
  Analysis including sIL‐2R                                                                            
  Age ≥70                              4.44              1.05‐18.7           0.04   2.03   1.19‐3.46   \<0.01
  ECOG Performance Status ≥2           3.26              0.83‐12.8           0.08   1.78   0.88‐3.62   0.11
  LDH \>Normal                         2.40              0.45‐12.9           0.30   1.70   0.94‐3.08   0.08
  Major organ involvement              1.01              0.22‐4.68           0.99   0.82   0.45‐1.52   0.53
  Stage ≥III                           0.75              0.09‐5.90           0.78   1.08   0.59‐2.02   0.79
  sIL‐2R ≥1300 U/mL                    4.45              1.04‐19.1           0.04   1.94   1.01‐3.72   0.05
  Analysis including TMTV                                                                              
  Age ≥70                              2.47              0.93‐6.57           0.07   2.23   1.32‐3.75   \<0.01
  ECOG Performance Status ≥2           1.47              0.64‐3.38           0.36   1.96   0.95‐4.01   0.07
  LDH \>Normal                         1.61              0.41‐6.22           0.48   2.14   1.20‐3.83   0.01
  Major organ involvement              1.15              0.39‐3.32           0.79   0.67   0.37‐1.22   0.19
  Stage ≥III                           0.88              0.19‐4.04           0.87   1.10   0.62‐1.95   0.74
  TMTV ≥150 cm^3^                      3.87              1.08‐13.8           0.04   3.30   1.82‐6.00   \<0.01
  Analysis including sIL‐2R and TMTV                                                                   
  Age ≥70                              2.48              0.91‐6.72           0.07   2.24   0.87‐3.83   0.08
  ECOG Performance Status ≥2           1.49              0.66‐3.39           0.34   1.87   0.75‐3.96   0.54
  LDH \>Normal                         1.60              0.41‐6.20           0.49   1.79   0.79‐2.85   0.21
  Major organ involvement              1.14              0.39‐3.29           0.81   1.02   0.38‐5.34   0.48
  Stage ≥III                           0.67              0.15‐3.04           0.61   1.10   0.57‐3.32   0.12
  sIL‐2R ≥1300 U/mL                    4.51              0.72‐28.5           0.11   2.02   0.74‐6.46   0.76
  TMTV ≥150 cm^3^                      1.23              0.17‐8.93           0.84   2.47   0.36‐5.48   0.13

ECOG, Eastern Cooperative Oncology Group; LDH; lactate dehydrogenase; OS, overall survival; sIL‐2R, soluble interleukin‐2 receptor.
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Subgroup analyses included the patients with NCCN‐IPI High‐Int and High (n = 49) demonstrated that the cutoff value of TMTV 150 cm^3^ stratified treatment outcomes in this poor prognostic group (5‐year OS; 75.0% vs 27.7%, *P = *0.0355, 5‐year EFS; 66.7% vs 29.7%, *P = *0.0493; Figure [5](#cam41973-fig-0005){ref-type="fig"}A, B). Similar results were obtained using the cutoff value of sIL‐2R 1300 U/mL (5‐year OS; 75.0% vs 25.9%, *P = *0.0182, 5‐year EFS; 58.3% vs 29.7%, *P = *0.0499; Figure [5](#cam41973-fig-0005){ref-type="fig"}C, D).

![Impacts of TMTV and sIL‐2R levels in patients with High and High‐intermediate risk by NCCN‐IPI. Kaplan‐Meier plots of OS (A) and EFS (B) according to TMTV, OS (C) and EFS (D) according to sIL‐2R in patients with High risk (n = 29) and High‐intermediate risk (n = 20) stratified by NCCN‐IPI are shown](CAM4-8-953-g005){#cam41973-fig-0005}

3.7. Validation of the results in the validation cohort {#cam41973-sec-0013}
-------------------------------------------------------

Finally, the prognostic impacts of serum levels of sIL‐2R and TMTV, and correlation between sIL‐2R and metabolic parameter were validated in the independent validation cohort composed of significantly younger patients with better PS, less advanced‐stage disease, and lower NCCN‐IPI scores than the training cohort (Table [1](#cam41973-tbl-0001){ref-type="table"}). The OS and EFS in this cohort were shown (Figure [S2](#cam41973-sup-0002){ref-type="supplementary-material"}). In terms of TMTV and sIL‐2R, there were no significant differences between patients in the training cohort and the validation cohort (Table [1](#cam41973-tbl-0001){ref-type="table"}). Kaplan‐Meier curves showed that OS and EFS rates in patients with TMTV ≥150 cm^3^ were again lower than in those with TMTV \<150 cm^3^ (5‐year OS; 87.0% vs 59.5%, *P = *0.016, 5‐year EFS; 72.8% vs 52.3%, *P = *0.0154; Figure [S3](#cam41973-sup-0003){ref-type="supplementary-material"}A, B).

The median serum sIL‐2R level at diagnosis was 1274 U/mL, ranging from 200 to 39 798 U/mL. Kaplan‐Meier curves showed that sIL‐2R ≥1300 U/mL was a strong prognostic factor both for worse OS and EFS (5‐year OS; 86.3% vs 61.8%, *P = *0.0188, 5‐year EFS; 85.0% vs 46.8%, *P = *0.000413; Figure [S3](#cam41973-sup-0003){ref-type="supplementary-material"}C, D). Pearson\'s correlation tests gave similar results that there were positive correlations between sIL‐2R and TMTV (*R* ^2^ = 0.461; *P* = 0.00000631; Figure [2](#cam41973-fig-0002){ref-type="fig"}B). In a univariate analysis, TMTV was associated with poor 5‐year OS, whereas sIL‐2R and TMTV were identified as poor prognostic factors for EFS (Table [2](#cam41973-tbl-0002){ref-type="table"}). In a multivariate analysis including sIL‐2R, age was an independent prognostic factor and there was a strong trend toward worse 5‐year OS in patients with higher sIL‐2R (Table [3](#cam41973-tbl-0003){ref-type="table"}). In another multivariate analysis including TMTV showed that age, LDH, and TMTV were independent prognostic factor for 5‐year OS (Table [3](#cam41973-tbl-0003){ref-type="table"}). Altogether, we could validate that both sIL‐2R and TMTV are promising prognostic biomarkers and there is a positive correlation between sIL‐2R and TMTV, suggesting that sIL‐2R is useful for extrapolation of TMTV.

4. DISCUSSION {#cam41973-sec-0014}
=============

Soluble IL‐2R is a soluble form of the α‐subunit of high‐affinity receptor for IL‐2 that consists of three subunits: α‐subunit, β‐subunit, and γ‐subunit. While resting lymphocytes, monocytes, and NK cells constitutively express the β‐ and γ‐subunits, the α ‐subunit of IL‐2R (IL‐2Rα) is constitutively expressed only on the cell surface of lymphoid neoplastic cells and transiently induced on the activated normal lymphocytes.[25](#cam41973-bib-0025){ref-type="ref"} Although the precise mechanism of sIL‐2R shedding is not clear, it has been shown that the release of sIL‐2R is proportional to its cell surface expression, suggesting that serum levels of sIL‐2R represent the numbers of IL‐2R α‐expressing lymphoma cells and activated lymphocytes.[26](#cam41973-bib-0026){ref-type="ref"}

Previous studies have shown the predictive role of pretreatment TMTV and sIL‐2R for survival in patients with FL [13](#cam41973-bib-0013){ref-type="ref"}, [27](#cam41973-bib-0027){ref-type="ref"}, [28](#cam41973-bib-0028){ref-type="ref"} and DLBCL.[11](#cam41973-bib-0011){ref-type="ref"}, [15](#cam41973-bib-0015){ref-type="ref"}, [16](#cam41973-bib-0016){ref-type="ref"} Ennishi et al reported that sIL‐2R \> 1000 mg/dL predicted worse OS and EFS after R‐CHOP in patients with newly diagnosed DLBCL. Goto et al reported that sIL‐2R ≥1300 U/mL predicted worse prognosis both in GCB‐like and in non‐GCB‐like DLBCL classified based on Hans criteria.[29](#cam41973-bib-0029){ref-type="ref"} The cutoff value of sIL‐2R in the current study was slightly different from those reported in previous studies.[15](#cam41973-bib-0015){ref-type="ref"}, [16](#cam41973-bib-0016){ref-type="ref"} Cutoff value of sIL‐2R in our study was determined using CLIA, while ELISA was used in Goto\'s report. Although it is possible that the different methods for sIL‐2R assessment could result in the different cutoff values, it could be also possible that the different endpoints used in ROC analyses performed by Goto et al and us resulted in the difference of cutoff values between these two studies; Goto et al used the median progression‐free survivals (PFS) as the endpoint, while we used EFS24. Ennishi et al arbitrarily used the median value of serum levels of sIL‐2R as the cutoff value.

We have extended these previous findings on the prognostic values of TMTV and serum levels of sIL‐2R at diagnosis. The primary aim of this study was to clarify the correlation between serum levels of sIL‐2R and TMTV and compare the role of these factors as prognostic biomarkers. We found significant positive correlation between serum levels of sIL‐2R and TMTV. Furthermore, sIL‐2R ≥1300 U/mL stratified patients with poor prognosis in an analogous manner to TMTV ≥150 cm^3^ did. These cutoff values also improved risk stratification of patients with NCCN‐IPI High and High‐Int.

Serum levels of sIL‐2R have been routinely measured in DLBCL patients since 1990s in Japan.[30](#cam41973-bib-0030){ref-type="ref"} This biomarker is also used as a major prognostic biomarker for transplant‐related GVHD in United States.[31](#cam41973-bib-0031){ref-type="ref"} Even though we have 4.3 PET units per 1 million people in Japan (3rd in the world), some hematology/oncology centers are not equipped with PET, and patients need to travel to the external PET facilities (OECD stat. 2017 <https://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT#>). Instead, we can know the serum levels of sIL‐2R within a day of blood sampling in many centers. In Japan, the costs associated with ^18^FDG‐PET and sIL‐2R are \~1000 and 40 USD, respectively. Thus, serum level of sIL‐2R is a promising biomarker that can be easily and inexpensively measured in clinical practice and have a great potential as a predictor of outcome in DLBCL patients; however, it should be noted that PET/CT is also useful for monitoring of tumor responses after treatment, suggesting that these two tests could work together in a complementary fashion. It was reported that profound reduction of TMTV from initial PET/CT to interim PET‐CT was associated with better prognosis, indicating that TMTV on interim PET/CT could be the useful biomarker in DLBCL*.* [32](#cam41973-bib-0032){ref-type="ref"} Further studies are required to determine whether serum levels of sIL‐2R after treatment could be correlated with TMTV on interim PET/CT.

The accurate evaluation of tumor burden at diagnosis became more important in the rituximab era, because high tumor amounts promote clearance of rituximab from the circulation both in mice and in humans; higher TMTV at diagnosis of DLBCL led to lower rituximab exposure and inferior OS and PFS,[33](#cam41973-bib-0033){ref-type="ref"} suggesting that rituximab dosing could be guided by tumor amount at diagnosis. Metavol^®^ is a free and open‐source software tool to measure TMTV from PET/CT scans. Although this software made measuring TMTV much easier, our data indicate that sIL‐2R also correlates with tumor burden and enables us to evaluate tumor burden in patients, in whom PET/CT evaluation is not available. It should be noted that serum level of sIL‐2R cannot function as all the same to PET/CT scan does, such as visualization the distribution of the tumor lesions in patients.

Our study has some limitations, including a retrospective setting, small sample size, rather low AUC in ROC analyses, diagnosis according to the previous 2008 WHO classification, lack of central review for pathological diagnosis, and use of R‐CHOP‐like chemotherapies in some patients. However, OS rate of 53.1% and EFS 45.4% at 5 years were consistent with previous studies, in which aged DLBCL patients were treated with similar regimens used in our study.[23](#cam41973-bib-0023){ref-type="ref"}, [24](#cam41973-bib-0024){ref-type="ref"}, [34](#cam41973-bib-0034){ref-type="ref"}, [35](#cam41973-bib-0035){ref-type="ref"} The difference in sIL‐2R measurement between the training and validation cohorts might impact our results; CLIA was used in the training cohort, while ELISA was used in the validation cohort. Although the upper normal limits of sIL‐2R in these two assays were similar (496 U/mL for CLIA and 500 U/mL for ELISA), it might be possible that serum sIL‐2R levels differ slightly with methods of measurement kits. At least, the cutoff value of sIL‐2R determined in the training cohort successfully stratified the outcome of the patients in the validation cohort. The correlation between CLIA‐based and ELISA‐based levels of sIL‐2R needs to be clarified in the future studies. Another limitation of the current study is that the cameras and equipments used for PET/CT imaging were different from those used in the validation cohort.

In summary, we for the first time showed positive correlation between the serum level of sIL‐2R and the quantitative parameter TMTV in patients with newly diagnosed DLBCL. sIL‐2R is easily measurable in the clinical practice and have a great potential to predict treatment outcomes and assess metabolic tumor burden of DLBCL patients.
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